Open-Label Phase 3 Long-Term Safety Study of Migalastat (AT1001-041)

Official Title: An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease

This is a long term, open label study of migalastat HCl (AT1001) in subjects with Fabry disease who completed treatment in a previous monotherapy trial with migalastat hydrochloride (HCl).

NCT01458119
Charrow, Joel M., MD
Interventional
No

Contact Information:

Joel Charrow, MD

312.227.6120